PeptideStack
5.2kquestions
20kanswers
220users

Why did two SWB lots of dulaglutide differ on content assay?

Asked 27 Apr 2025Modified 12 months agoViewed 12k times
29

Numbers first: SWB · dulaglutide.

I have a result I cannot explain, and I would rather diagnose it than guess.

I have checked the obvious explanations and eliminated the two easiest ones.

What is the most likely explanation, and how would I confirm it?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

438 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

436 questions
shareeditfollowflag
TM
askedthabo_maseko20k2727 Apr 2025

5 Answers

Accepted answer first, then by votes
84

Accepted answer

Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
DF
answered · acceptedDr_Colm_Fitzhenry85k24825 Jun 2025
I would gently push back on the second point — the evidence there is thinner than stated. – n_takahashi 32 days ago
Adding for future readers: the certificate should carry the lot number, not just a batch code. – tandem_gradient 3 months ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
71

Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

Worth being precise here: the statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
OB
answeredone_ml_bac12k166 Jul 2025
6The distinction between purity and content cannot be repeated often enough here. – g_paskevicius 4 months ago
add a comment
37

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

The relevant detail is that the sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

edited 13 Aug 2025 by t_oyelaran — added the placebo-arm figures

shareimprove this answerflag
TO
answeredt_oyelaran41k3829 Jul 2025
31

The failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
VV
answeredvoid_volume13k1618 Jul 2025
3Two of us worked through this independently and arrived here, so it is at least reproducible. – vialroom 9 months ago
2Worth adding that the method section is where the answer usually is. – Dr_Wren_Halliday 7 months ago
add a comment
26

Worth being precise here: if a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
OF
answeredorla_ferriter47k3823 May 2025
Note that the label instructions differ between agents on precisely this point. – ilaria_bertone 1 days ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.